Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)
Upcoming SlideShare
Loading in...5

Like this? Share it with your network


Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)






Total Views
Views on SlideShare
Embed Views



2 Embeds 5 3 2


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • I am presenting this article on The Efficacy and Safety of EPO in the Critically Ill Patients which was published in NEJM for 2 reasons. 1) I was very involved with this study and recruited many of the Lead Investigators in the Midwest and 2) This study was done in Critical Care Patients which I thought would be appropriate for Today

Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set) Presentation Transcript

  • 1. Presentation of NEJM Article on Efficacy & Safety of Epoetin Alfa in Critically Ill Patients
    • William C Lambert, M.D.
  • 2. Original Article Efficacy and Safety of Epoetin Alfa in Critically Ill Patients Howard L. Corwin, M.D., Andrew Gettinger, M.D., Timothy C. Fabian, M.D., Addison May, M.D., Ronald G. Pearl, M.D., Ph.D., Stephen Heard, M.D., Robert An, Ph.D., Peter J. Bowers, M.D., Paul Burton, M.D., Ph.D., Mark A. Klausner, M.D., Michael J. Corwin, M.D., for the EPO Critical Care Trials Group N Engl J Med Volume 357(10):965-976 September 6, 2007
  • 3. Hypothesis
    • Patients with anemia of critical illness often suffer impaired RBC production and an absence of elevated erythropoetin concentrations
    • Therapy with Recombinant Human Erythropoietin (epoetin alfa) might raise the Hgb Concentrations and reduce the need for red-cell transfusions
  • 4. Methods
    • In this randomized, placebo-controlled trial, the investigators administered epoetin alfa or placebo to 1460 medical, surgical, or trauma patients between 48 and 96 hours after admission to the intensive care unit
    • Epoetin alfa (40,000 U) or placebo was administered SC on day 1 and weekly for a maximum 3 weeks, patients were followed for 140 days
  • 5. Primary Endpoint
    • Percentage of Patients who Received a Red Cell Transfusion Between Days 1 and 29
  • 6. Secondary Endpoints
    • Number of Red Cells Transfused
    • Mortality
    • Change in Hemoglobin Concentration From Baseline
  • 7. Inclusion Criteria
    • All Patients Admitted to Medical, Surgical or Medical-Surgical ICU and Remained in the ICU for 2 Days
    • Age 18 years or older
    • Hemoglobin Concentration of Less than 12g /deciliter
    • Written Informed Consent
  • 8. Exclusion Criteria
          • Expected Discharge from ICU within 48 hours after the 2 nd day in ICU
          • Acute Ischemic Heart Disease during the ICU stay
          • Stay of more than 48 hours duration in the ICU of a tranferring hospital
          • Presence of a left ventricular assist device
          • History of a pulmonary embolus
          • Deep venous thrombosis
          • Ischemic stroke
          • Dialysis for any indication
          • Uncontrolled Hypertension after adequate antihypertensive therapy
          • New-onset seizures within the past 3 months
          • 3 rd degree burns on more than 20% of the body-surface area
  • 9. Exclusions Cont’d
    • Pregnancy or Lactation
    • Diagnosis of Acute clinically significant GI bleeding on admission
    • Transfusion at time of planned enrollment
    • Treatment of epoetin alfa within the past 30 days
    • Inability or unwillingness to receive blood products
    • Participation in another study
    • Hypersensitivity to epoetin alfa
  • 10. Screening and Enrollment of Study Patients Corwin HL et al. N Engl J Med 2007;357:965-976
  • 11. Summary of Data on Red-Cell Transfusion Corwin HL et al. N Engl J Med 2007;357:965-976
  • 12. Hemoglobin Concentration
    • Day 29, the increase in the Hgb Concentration from baseline was Greater in the EPO than in Placebo (1.6 vs 1.2 ) g/deciliter
    • Day 42, Hgb Concentrations in 2 study groups were not significantly different
    • [p
  • 13. Mortality at Day 29 and Day 140 in the Intention-to-Treat Population Corwin HL et al. N Engl J Med 2007;357:965-976
  • 14. Serious Adverse Events Corwin HL et al. N Engl J Med 2007;357:965-976
  • 15. Conclusions
    • Treatment with epoetin alfa did not reduce the percentage of patients receiving a red-cell transfusion (the primary outcome)
    • Appeared to reduce mortality in patients with trauma
  • 16. Questions ?
  • 17. THANK YOU